[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Loma Linda University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":611},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,46,0,25,[9,43,65,91,118,145,164,189,221,240,262,287,311,342,361,389,409,428,447,470,494,515,541,561,583],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100461159","limited-ankle-dorsiflexion-and-effect-on-single-limb-squats-in-individuals-with-patellofemoral-pain-100461159",false,"NCT05285007","Limited Ankle Dorsiflexion and Effect on Single Limb Squats in Individuals With Patellofemoral Pain","Limited Ankle Dorsiflexion and Effect on Single Limb Squats in Individuals With Patellofemoral Pain: Interventions and Outcomes in a Randomized Clinical Trial","Inclusion Criteria:\n\n* History of active Patellofemoral Pain for at least 6 months\n* No clinic based therapeutic interventions for a 6-month period prior to testing\n* Females aged 18-59 years' old\n* Limited ankle dorsiflexion as noted by \\\u003C45degs using the weight bearing lunge test\n\nExclusion Criteria:\n\n* History of musculoskeletal surgery or fractures on the tested leg or lumbar spine that could affect their biomechanics during the study\n* History of soft tissue or skeletal abnormalities in the tested limb\n* Current knee effusion\n* Resting pain greater than 5\u002F10",true,"FEMALE","18 Years","59 Years",{"count":22,"type":23},60,"ESTIMATED","INTERVENTIONAL",[26],"NA","The purpose of this graduate student research study is to investigate the relationship between limited ankle dorsiflexion and the potential effects on a single limb squat task in the Patellofemoral\u002FKnee Pain population.",[29],"Patellofemoral Pain","RECRUITING","2026-08-19",{"date":33,"type":34},"2026-08-20","ACTUAL",{"date":36,"type":34},"2022-03-02",{"date":38,"type":23},"2027-05",{"name":40,"class":41},"Loma Linda University","OTHER",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":50,"minAge":19,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":42},"100445771","dd-cfdna-and-treg-in-prediction-of-kidney-transplant-acute-rejection-100445771","NCT05084768","Dd-cfDNA and Treg in Prediction of Kidney Transplant Acute Rejection","Integration of Donor-derived Cell-free DNA With HLA-DR+TNFR2+ Regulatory T Cell in the Prediction of Acute Rejection and Graft Function After Kidney Transplantation","Inclusion Criteria:\n\n* Adult kidney transplant candidates\u002Frecipients\n\nExclusion Criteria:\n\n* Age less than 18\n* Multi-organ transplants\n* Kidney transplant candidates\u002Frecipients with HIV\n* Kidney transplant candidates\u002Frecipients with HCV","ALL",{"count":52,"type":23},150,"OBSERVATIONAL","Acute rejection after kidney transplantation should ideally be diagnosed prior to immunologic injury in a non-invasive fashion in order to improve long-term graft function. Donor-derived cell-free DNA (ddcfDNA) is a promising method to do so as it is elevated prior to acute rejection and has good predictive performance especially for antibody-mediated and high severity T-cell mediated rejection. Its ability to predict low severity T-cell mediated rejection and future graft function remains equivocal. Regulatory T cells (Tregs) are essential in transplant tolerance by suppressing effector immune responses. Circulating post-transplant highly suppressive HLA-DR+ Tregs were reduced in recipients who developed acute rejection. Preliminary results in a cohort including predominantly low severity T-cell mediated rejection also showed that pre-transplant circulating highly suppressive TNFR2+ Tregs were reduced in and could predict acute rejection. Integrating dd-cfDNA with HLA-DR+TNFR2+ Treg could improve the predictive performance for acute rejection especially of low severity and potentially predict graft function. Plasma dd-cfDNA and HLA-DR+TNFR2+ Tregs will be measured in 150 kidney transplant recipients at scheduled intervals during the first 6 months post-transplant. Predictive accuracy of a model integrating ddcfDNA and HLA-DR+TNFR2+ Treg for acute rejection will be tested using ROC curve analysis and multivariate logistic regression. Predictive accuracy for 1-year graft function will be tested using multivariate linear regression. High predictive performance for acute rejection and graft function using a model integrating dd-cfDNA and HLA-DR+TNFR2+ Treg would help identify kidney transplant recipients at immunologic risk early on and allow personalization of immunosuppression accordingly.",[56,57],"Acute Rejection of Renal Transplant","Graft Failure",{"date":59,"type":34},"2026-08-21",{"date":61,"type":34},"2020-12-07",{"date":63,"type":23},"2026-10-01",{"name":40,"class":41},{"id":66,"slug":67,"hasResults":12,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":12,"sex":50,"minAge":19,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":24,"phases":75,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":42},"100578248","occupational-therapy-for-adults-who-have-experienced-intimate-partner-violence-ipv-100578248","NCT06808828","Occupational Therapy for Adults Who Have Experienced Intimate Partner Violence (IPV)","Occupational Therapy for Adults Who Have Experienced Intimate Partner Violence","IPV","Inclusion Criteria:\n\n* Male or Female 18 years of age or older receiving services from a domestic violence organization\n\nExclusion Criteria:\n\n* None","70 Years",{"count":7,"type":23},[26],"The purpose of this graduate student research study is to understand the effectiveness of an occupational therapy program in a domestic violence shelter. It is expected that participation will last about 6 weeks. Subjects will complete pretests involving lifestyle assessments and a coping scale and then participate in 8 occupational therapy sessions during the 4 weeks of program implementation. The occupational therapy sessions will last approximately 90 minutes. After the program is completed, subjects will complete the posttests.\n\nProcedures and Activities. You will be asked to:\n\nComplete a series of questionnaires about your health, well-being, and daily activities.\n\nParticipate in 8 OT sessions that may include activities such as journaling, positive self-talk, coping skills methods, and grounding exercises.\n\nComplete the posttests.",[78],"Domestic Violence",[80,81,82],"domestic violence","intimate partner violence","occupational therapy","2026-07-31",{"date":85,"type":34},"2026-08-04",{"date":87,"type":34},"2025-02-03",{"date":89,"type":23},"2026-12",{"name":40,"class":41},{"id":92,"slug":93,"hasResults":12,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":12,"sex":50,"minAge":98,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":24,"phases":102,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":42},"100635970","the-effects-of-mango-on-gut-health-markers-100635970","NCT07559604","The Effects of Mango on Gut Health Markers","The Effects of Fresh Mango Consumption on Gut Permeability Markers and Short Chain Fatty Acid Production in Individuals With Prediabetes","Inclusion Criteria:\n\n* Participated in NCT06159543\n\nExclusion Criteria:\n\n* Did not participate in NCT06159543","40 Years","60 Years",{"count":101,"type":23},31,[26],"This is an ancillary study of NCT06159543, which was a clinical trial that examined the effect of a 12-week 1.5 cups daily mango crossover intervention on cardiometabolic outcomes in individuals with prediabetes, male and female, and 40-60 years of age. The goal of this ancillary study is to test the effect of the mango intervention on gut health markers in individuals with prediabetes. The main questions it aims to answer are:\n\n1. What is the effect of 1.5 cups per day of fresh mango over 12 weeks on indicators of gut permeability as measured by lipopolysaccharide-binding protein (LBP) and soluble CD14 (sCD14)?\n2. What is the effect of 1.5 cups per day of fresh mango over 12 weeks on microbiome modulation as estimated by short chain fatty acids (SCFAs)?\n\nSecondarily:\n\n1. Is LBP a mediator of the relationship between systemic inflammation \\[as determined by C-reactive protein, E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1)\\] and SCFAs?\n2. Is LBP a mediator of the relationship between insulin resistance \\[as determined by HOMA-IR\\] and SCFAs?\n3. Is sCD14 a mediator of the relationship between systemic inflammation \\[as determined by C-reactive protein, E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1)\\] and SCFAs?\n4. Is sCD14 a mediator of the relationship between insulin resistance \\[as determined by HOMA-IR\\] and SCFAs?\n\nResearchers will compare the 12 weeks participants consume mango to the 12 weeks the participants are not consuming mango to see if there are differences in LBP, sCD14, and SCFAs.\n\nAs noted, this is an ancillary study of NCT06159543. Fasting blood was collected at baseline, and at the end of each phase of NCT06159543. This blood will be used to analyze LBP, sCD14 and SCFAs. Fasting blood and insulin were analyzed in NCT06159543, and will used to calculate HOMA-IR in the ancillary study. C-reactive protein, E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) will be analyzed NCT06159543.",[105,106,107,108],"Gut Health","LBP","Short Chain Fatty Acids","sCD14","NOT_YET_RECRUITING","2026-07-08",{"date":112,"type":34},"2026-07-10",{"date":114,"type":23},"2026-09",{"date":116,"type":23},"2027-12",{"name":40,"class":41},{"id":119,"slug":120,"hasResults":12,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":17,"sex":50,"minAge":19,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":24,"phases":127,"briefSummary":129,"conditions":130,"keywords":133,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":140,"startDateStruct":141,"completionDateStruct":142,"leadSponsor":143,"locationsCount":144},"100602516","phase-3-effectiveness-of-toothpaste-tablets-on-plaque-gingival-health-and-caries-experiences-100602516","NCT07124533","Effectiveness of Toothpaste Tablets on Plaque, Gingival Health and Caries Experiences","Effectiveness of Toothpaste Tablets on Plaque, Gingival Health and Caries Experiences: A 6-week Randomized Controlled Trial","Inclusion Criteria:\n\n1. Subjects are 18 years or older;\n2. Subjects who will comply with study protocol;\n3. Subjects who can read and understand the consent form;\n4. Subjects available during the study period;\n5. Subjects have more than 20 teeth.\n\nExclusion Criteria:\n\n1\\. Subjects under the age of 18.",{"count":126,"type":23},50,[128],"PHASE3","Objectives: To evaluate the effectiveness of toothpaste tablets when compared to conventional dentifrices in removing plaque.\n\nMethods: 50 participants are randomized into two groups: Denttabs toothpaste tablets (T) and Colgate's Cavity Protection toothpaste (P). Both groups utilize their assigned dentifrice for 6 weeks. A pre and post-assessment measures the Gingival Index (GI) and Plaque Index (PI) and Decayed, Missing and Filled Teeth (DMFT). A questionnaire on the use of the product is distributed at the end of the study.",[131,132],"Gingival Inflammation","Dental Caries",[134,135,136,137,138,139],"Gingival Index","Plaque Index","Dentifrice","Toothpaste Tablets","Caries Experiences","Consumer Satisfaction",{"date":112,"type":34},{"date":89,"type":23},{"date":89,"type":23},{"name":40,"class":41},2,{"id":146,"slug":147,"hasResults":12,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":17,"sex":50,"minAge":19,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":24,"phases":154,"briefSummary":155,"conditions":156,"keywords":158,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":160,"startDateStruct":161,"completionDateStruct":162,"leadSponsor":163,"locationsCount":4},"100595423","regenerative-outcomes-for-peri-implant-bony-defects-using-amnion-chorion-barrier-vs-collagen-membrane-100595423","NCT07032259","Regenerative Outcomes for Peri-implant Bony Defects Using Amnion-chorion Barrier vs. Collagen Membrane","Regenerative Outcomes for Peri-implant Bony Defects Using Amnion-chorion Barrier vs. Collagen Membrane: a Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Systemically healthy adults (≥18 years) with a diagnosed peri-implantitis lesion requiring surgical intervention of any ethnicity\n* Comprehension of treatment plan and research project.\n* Presence of a single implant in function for at least one year.\n* Radiographic evidence of peri-implant bone loss not exceeding one-third of the implant length.\n* 2-3 wall defects amenable to guided bone regeneration (GBR).\n* Screw-retained, posterior, self-cleansing implant prosthesis.\n* Commitment to maintaining oral hygiene and attending follow-up visits.\n\nExclusion Criteria:\n\n* Patients who have had a history of periodontitis, diabetes, smoking habit, or have been prescribed medications that may interfere with bone healing and metabolism\n* Patients with allergies to any treatment devices\n* Patients who have a lack of keratinized mucosa (\\\u003C2 mm), or positioning for implants or restorative designs that compromise oral hygiene\n* Peri-implant bone defects not attributable to peri-implantitis (e.g. surgical iatrogenic, trauma)\n* Anterior implant restorations (#'s 6-11, #'s 22-27) or cement-retained restorations",{"count":153,"type":23},56,[26],"The purpose of this study is to compare the clinical and radiographic outcomes of two different barrier membranes-amnion-chorion membranes (ACM) and conventional collagen membranes-used in guided bone regeneration (GBR) procedures for the treatment of peri-implantitis. Both membranes are commonly used in clinical practice; however, this study aims to determine whether ACM offers greater benefits in terms of peri-implant probing depth reduction, radiographic bone fill, and patient-reported post-operative healing outcomes. The findings may help inform surgical decision-making and support the use of ACM as a more effective regenerative material for managing peri-implant bony defects.",[157],"Peri-Implantitis",[159],"Peri-implantitis",{"date":112,"type":34},{"date":89,"type":23},{"date":116,"type":23},{"name":40,"class":41},{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":12,"sex":172,"minAge":19,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":24,"phases":175,"briefSummary":176,"conditions":177,"keywords":179,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":184,"startDateStruct":185,"completionDateStruct":186,"leadSponsor":188,"locationsCount":42},"100579737","patient-reported-experiences-with-sparing-external-oblique-fascia-vs-standard-inguinal-orchiectomy-100579737","NCT06828185","Patient Reported Experiences With Sparing External Oblique Fascia Vs Standard Inguinal Orchiectomy","Patient Reported Experiences With Sparing ExteRnal Oblique Fascia Vs Standard Inguinal OrchiEctomy","PRESERVE","Inclusion Criteria:\n\n* Participants undergoing radical orchiectomy for suspected testicular malignancy\n* Testicular malignancy can be germ cell tumor or non germ cell tumors, including paratesticular tumors as long as a radical orchiectomy is planned\n* Participants over 18 years of age who can provide informed consent\n* Participants not currently using opiates for another reason\n* Regional and metastatic patients are allowed, as long as participant does not require opiates for pain related to metastatic disease\n* No contraindication for participant to receive standardized medication pathway in the peri-operative period.\n\nExclusion Criteria:\n\n* Clinical T4 disease\n* History of illicit substance abuse (including prior opioid abuse) except for marijuana\n* Participants who underwent chemotherapy or radiotherapy prior to orchiectomy\n* Opioid use within 1 month of study enrollment\n* Participants with large testis masses requiring skin incision larger than 8 cm in size.\n* Participants with large testis masses requiring orchiectomy through an incision other than the standard transverse inguinal incision (i.e. hockey stick incision, vertical incision)","MALE",{"count":174,"type":23},80,[26],"The purpose of this study is to evaluate the difference in patient-reported postoperative outcomes between two standard-of-care surgical techniques for radical orchiectomy (inguinal orchiectomy versus external oblique fascia sparing orchiectomy) for treatment of patients with suspected testicular malignancy. The main questions it aims to answer are:\n\n1. Does sparing the external oblique fascia during orchiectomy reduce pain after surgery?\n2. Is there a difference in narcotic consumption after surgery?\n3. Is there a difference in neuropathic pain after surgery?\n4. Is there a difference in complications after surgery?",[178],"Testicular Cancer",[180,181,182,183],"orchiectomy","postoperative pain","testis cancer","germ cell tumors",{"date":112,"type":34},{"date":89,"type":23},{"date":187,"type":23},"2029-09",{"name":40,"class":41},{"id":190,"slug":191,"hasResults":12,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":12,"sex":50,"minAge":19,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":24,"phases":198,"briefSummary":199,"conditions":200,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":216,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":220,"locationsCount":42},"100569296","the-effects-of-endotracheal-suctioning-on-pain-and-serum-markers-100569296","NCT06692400","The Effects of Endotracheal Suctioning on Pain and Serum Markers","The Impact of Endotracheal Suctioning on Pain, Hypoxia, and Oxidative Stress Biomarkers in Intubated Adult ICU Patients: A Controlled Trial","Inclusion Criteria:\n\n* Adults (aged 18 years and older)\n* Current diagnosis of flu, pneumonia, COVID, or sepsis\n* Intubated and receiving mechanical ventilation.\n* Have arterial lines placed\n* Require endotracheal suctioning as part of their care\n\nExclusion Criteria:\n\n* Patients receiving neuromuscular blocking agents\n* Contraindications for blood draws (hemoglobin levels below 8.0 g\u002FdL; Jehovah's Witness)",{"count":197,"type":23},110,[26],"The goal of this experimental study is to understand if endotracheal tube (ETT) suctioning increases pain and causes stress on the body in intubated adult ICU patients. These patients are already on ventilators, which means they need suctioning to keep their airways clear, but this procedure may be uncomfortable and cause stress.\n\nThe main questions this study aims to answer are:\n\nDoes ETT suctioning raise pain levels as measured by the Critical-Care Pain Observation Tool (CPOT)? Does ETT suctioning increase certain chemicals in the blood (hypoxanthine, xanthine, and uric acid) that show stress and lack of oxygen in the body? Researchers will compare patients who have ETT suctioning (intervention group) with those who do not have suctioning during the study period (control group) to see if there are differences in pain and blood markers of stress.\n\nParticipants will:\n\nHave pain measured before and after suctioning using the CPOT. Have blood samples taken from an existing line at three time points: 5 minutes before, 5 minutes after, and 30 minutes after suctioning.\n\nProvide demographic information (like age, gender, and diagnosis) from medical records.\n\nThis research will help improve how pain is managed for ICU patients who cannot speak for themselves, potentially leading to better pain relief methods in the future.",[201,202,203,204,205,206,207,208,209,210,211,212,213,214,215],"Intensive Care Unit ICU","Intubation","Critical Illness","Mechanical Ventilation","Pain Measurement","Pain, Procedural","Oxidative Stress","Hypoxia","Biomarkers \u002F Blood","Adult","Uric Acid","Sepsis","COVID","Influenza","Pneumonia",{"date":112,"type":34},{"date":218,"type":34},"2025-01-30",{"date":89,"type":23},{"name":40,"class":41},{"id":222,"slug":223,"hasResults":12,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":12,"sex":50,"minAge":228,"maxAge":19,"enrollmentInfo":229,"targetDuration":4,"studyType":24,"phases":231,"briefSummary":233,"conditions":234,"keywords":4,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":236,"startDateStruct":237,"completionDateStruct":238,"leadSponsor":239,"locationsCount":4},"100558380","phase-4-daily-iron-vs-every-other-day-iron-for-pediatric-patients-with-ida-100558380","NCT06550362","Daily Iron vs Every-other-day Iron for Pediatric Patients With IDA","A Randomized Controlled Trial Comparing Daily Oral Iron Administration to Every Alternate Day Iron Administration in the Treatment of Iron Deficiency Anemia in Pediatric Patients.","Inclusion Criteria:\n\n* Confirmed Iron Deficiency Anemia\n* Pediatric patients (1-18 years of age) without regard of gender, race, ethnicity nor language.\n* Able and willing to take oral iron (tablet or liquid).\n\nExclusion Criteria:\n\n* Pregnant or lactating patients\n* Known allergies or intolerance to oral iron formulations\n* Concomitant chronic medical conditions affecting iron metabolism\n* Short gut syndrome\n* Celiac disease\n* Inflammatory bowel disease\n* Cancer\n* Chronic kidney disease\n* Blood transfusions in the past 3 months\n* IV iron administration in the past 3 months\n* Oral iron supplementation in the past 2 weeks","1 Year",{"count":230,"type":23},100,[232],"PHASE4","Iron Deficiency Anemia (IDA) is a prevalent global health issue affecting a significant proportion of the population, including children. While daily oral iron supplementation is a common approach to treat IDA, concerns regarding side effects and compliance have led to exploration of alternative dosing schedules, such as every-other-day. This study aims to investigate the efficacy and safety of daily versus every other day oral iron supplementation in the management of IDA in pediatric patients.",[235],"Iron Deficiency Anemia",{"date":112,"type":34},{"date":89,"type":23},{"date":38,"type":23},{"name":40,"class":41},{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":17,"sex":50,"minAge":19,"maxAge":247,"enrollmentInfo":248,"targetDuration":4,"studyType":24,"phases":250,"briefSummary":251,"conditions":252,"keywords":255,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":258,"startDateStruct":259,"completionDateStruct":260,"leadSponsor":261,"locationsCount":42},"100533703","immune-and-cognitive-benefits-of-mango-intake-in-young-adults-100533703","NCT06229262","Immune and Cognitive Benefits of Mango Intake in Young Adults","Immune and Cognitive Benefits of Mango Intake in Young Adults: A Randomized Trial","Inclusion Criteria:\n\n* Male and female college students aged 18-30 years\n\nExclusion Criteria:\n\n* known intolerance or allergy to mangos\n* regular intake of mangos and\u002For fruits of a similar nutritional content such as peach, nectarine, papaya, apricot and cantaloupe\n* using cognition and\u002For immune-boosting supplements or vitamins\n* recent exposure to antibiotics and corticoids\n* uncontrolled chronic diseases and mental illnesses, clinical depression, and immunocompromised state","30 Years",{"count":249,"type":23},54,[26],"The main objectives of our proposed study are to determine the effects of mango consumption on immune and cognitive functions in free-living college going young adults aged 18-30 years",[253,254],"Cognition","Immunity",[256,254,257],"Mango","cognition",{"date":112,"type":34},{"date":89,"type":23},{"date":116,"type":23},{"name":40,"class":41},{"id":263,"slug":264,"hasResults":12,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":268,"eligibilityCriteria":269,"healthyVolunteers":12,"sex":50,"minAge":270,"maxAge":271,"enrollmentInfo":272,"targetDuration":4,"studyType":24,"phases":273,"briefSummary":274,"conditions":275,"keywords":277,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":282,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":286,"locationsCount":144},"100407654","melatonin-adolescent-research-study-100407654","NCT04588233","Melatonin Adolescent Research Study","Understanding the Impact of Melatonin Use on Adolescent Functioning: A Pilot and Feasibility Trial of the Melatonin Adolescent Research Study (MARS)","MARS","Inclusion Criteria:\n\n* Self-identified sleep difficulties (e.g., difficulty falling asleep, staying asleep, or premature waking resulting in short or disrupted sleep).\n* Ages 13 to 17 years old\n* Able to understand, read, and write in English\n* Melatonin naive\n\nExclusion Criteria:\n\n* Obesity\n* Use of psychiatric medication\n* Drug(s), or supplements known to affect sleep\n* History of head injury or concussion with loss of consciousness \\>1 minute\n* Daily consumption of \\>1 caffeinated beverage\n* Risk for any organic sleep disorder (e.g., obstructive sleep apnea, restless leg syndrome)","13 Years","17 Years",{"count":174,"type":23},[26],"The present study will use a within-person, randomized cross-over experimental design to test the effects of exogenous melatonin supplementation on the sleep and daytime functioning of typically developing adolescents with short or disrupted sleep of behavioral origins (i.e., difficulty falling asleep, staying asleep, or premature waking resulting in short or disrupted sleep not attributed to an organic sleep condition).",[276],"Sleep Disorders in Children",[278,279,280,281],"Melatonin","Sleep Disturbance","Adolescents","Daytime Functioning",{"date":112,"type":34},{"date":284,"type":34},"2021-09-15",{"date":38,"type":23},{"name":40,"class":41},{"id":288,"slug":289,"hasResults":12,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":293,"eligibilityCriteria":294,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":295,"enrollmentInfo":296,"targetDuration":4,"studyType":24,"phases":298,"briefSummary":299,"conditions":300,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":42},"100636043","impact-of-lactation-antenatal-teaching-by-clinicians-and-healthcare-providers-100636043","NCT07560553","Impact of Lactation Antenatal Teaching by Clinicians and Healthcare Providers","Impact of Lactation Antenatal Teaching by Clinicians and Healthcare Providers: Randomized Control Trial","iLATCH","Inclusion Criteria:\n\n* Nulliparous mothers\n* Multiparous mothers who did not breastfeed previous children or breastfed previous children for less than 6 months\n\nExclusion Criteria:\n\n* Mothers planning to use formula\n* Multiparous mothers who previously breastfed for more than 6 months\n* Mothers with HIV\n* Mothers with a history of breast reduction surgery\n* Infants with major birth defects that may impede growth or feeding, such as cleft lip and\u002For palate, cardiac defects, and gastrointestinal defects","45 Years",{"count":297,"type":23},196,[26],"The purpose of this study is to increase the rate of exclusive breastfeeding at 6 weeks postpartum in the Inland Empire by addressing inadequate antenatal breastfeeding education for patients.",[301,302],"Pregnancy Related","Breast Feeding, Exclusive","2026-06-18",{"date":305,"type":34},"2026-06-23",{"date":307,"type":34},"2026-06-16",{"date":309,"type":23},"2028-06",{"name":40,"class":41},{"id":312,"slug":313,"hasResults":12,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":317,"eligibilityCriteria":318,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":319,"targetDuration":4,"studyType":24,"phases":321,"briefSummary":322,"conditions":323,"keywords":327,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":144},"100549784","integrating-chws-into-prenatal-care-for-maternal-smoking-cessation-100549784","NCT06438549","Integrating CHWs Into Prenatal Care for Maternal Smoking Cessation","Integrating CHWs Into Prenatal Care for Maternal Smoking Cessation: A Pilot Feasibility Study","SFHOPE","Inclusion Criteria:\n\n* \\\u003C 24 weeks pregnant\n* age \\> 18 years,\n* current smokers (100 cigarettes in their lifetime and \\>3 cigarettes per day in the last 7 days; including poly-tobacco use, combining cigarettes with non-combustible products) confirmed by expired carbon monoxide (CO)\n* willing to quit smoking and set a quit date in the next 2 weeks upon enrolling\n* enrolled in prenatal care at Loma Linda University Health (LLUH) or Riverside University Health System (RUHS)\n\nExclusion Criteria:\n\n* severe mental health problems that prevent informed consent and\u002For CHW intervention\n* women who were on Nicotine Replacement Therapy (NRT) or enrolled in a cessation program within 30 days\n* unwillingness to participate in audio-recorded key informant interviews or focus groups",{"count":320,"type":23},105,[26],"This develops a novel behavioral tobacco cessation program for pregnant smokers in San Bernardino County.",[324,325,326],"Tobacco Use","Tobacco Use Cessation","Tobacco Use in Childbirth",[328,329,330,331,332,333],"prevention","treatment","disparities and social inequality","tobacco use cessation","community health worker","pregnant smokers","2026-06-05",{"date":336,"type":34},"2026-06-08",{"date":338,"type":34},"2024-05-24",{"date":340,"type":23},"2027-08",{"name":40,"class":41},{"id":343,"slug":344,"hasResults":12,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":4,"eligibilityCriteria":348,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":349,"targetDuration":4,"studyType":24,"phases":351,"briefSummary":352,"conditions":353,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":356,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":360,"locationsCount":42},"100542156","wound-irrigation-with-saline-versus-hypodilute-chlorhexidine-after-cesarean-section-wishes-study-100542156","NCT06339203","Wound Irrigation With Saline Versus Hypodilute-chlorhexidine After Cesarean Section (WISHES Study)","Wound Irrigation With Saline Versus Hypodilute-chlorhexidine After Cesarean Section: a Randomized Clinical Trial (WISHES Study)","Inclusion Criteria:\n\n* Age 18 or older\n* Singleton pregnancy\n* Planned cesarean delivery at gestational age 37 weeks or later at Loma Linda University Children's Hospital\n* Planned post-operative follow up with Loma Linda OBGYN\n* Speak English or Spanish\n* At least one of the following medical complications: Obesity BMI\\>= 30kg\u002Fm2, Diabetes, Spontaneous rupture of membranes, Intraamniotic infection\n\nExclusion Criteria:\n\n* Emergency cesarean delivery",{"count":350,"type":23},400,[26],"This investigator-initiated, open-label, randomized controlled trial will explore the effects of two treatment arms, comparing standard treatment with normal saline against Irrisept, a jet lavage solution containing a low concentration of Chlorhexidine Gluconate (CHG) at 0.05% in 99.95% sterile water for irrigation. The study aims to evaluate the impact on postoperative wound healing in patients who have undergone cesarean delivery.",[354,355],"Cesarean Section Complications","Cesarean Section; Infection",{"date":336,"type":34},{"date":358,"type":34},"2024-06-05",{"date":89,"type":23},{"name":40,"class":41},{"id":362,"slug":363,"hasResults":12,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":4,"eligibilityCriteria":367,"healthyVolunteers":17,"sex":50,"minAge":368,"maxAge":369,"enrollmentInfo":370,"targetDuration":4,"studyType":24,"phases":372,"briefSummary":373,"conditions":374,"keywords":376,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":42},"100469135","building-resilient-families-100469135","NCT05388864","Building Resilient Families","A Multi-Component Intervention to Strengthen Families With Adverse Childhood Experiences (ACEs)","Inclusion Criteria:\n\n* Ages 3-11\n* Seen for a well-child visit at a participating pediatric clinic\n\nExclusion Criteria:\n\n* \\\u003C 3 years or \\>11 years of age\n* Significant congenital medical problems\n* Previous participation in parenting program (last 12 months)\n* Sibling enrollment in current study","3 Years","11 Years",{"count":371,"type":23},340,[26],"Prior research suggests that it is possible to improve health outcomes in children with ACEs through multi-component interventions. The challenge for most communities is that health and education systems are fragmented and fail to accommodate families based upon different levels of need. This study utilizes cross-sectoral partnerships to mobilize three vectors (pediatricians, community health workers and parenting educators) to optimize the delivery of vital information and resources to a diverse population of families with ACEs. All vectors are trained in an evidence-informed curriculum to strengthen families and build youth resilience. The study design is a randomized controlled trial of 340 families of children between the ages of 3 to 11 who are generally healthy and have recently seen a pediatrician for a well-child visit.\n\nTo evaluate the efficacy of this intervention, pediatric patients are invited to participate in repeat evaluations within 2 weeks, 3 months, 6 months, and 12 months after their well-child visit. The study will evaluate the following: 1) the association between Child-ACE scores and biomarkers of toxic stress at baseline in children age 3-11 years old; 2) whether the intervention reduces toxic stress and child health and psychosocial problems at follow-up for children with ACEs compared to usual well-child care for children with ACEs; and 3) the impact of mediating and moderating variables. These results will demonstrate that for families with ACEs the intervention will decrease toxic stress associated with ACEs, improve health outcomes, and reduce health disparities.",[375],"Adverse Childhood Experiences",[377,378,328,379,380,381],"adverse childhood experiences","pediatrics","preventive health services","quality improvement","childhood abuse and neglect",{"date":383,"type":34},"2026-06-09",{"date":385,"type":34},"2022-05-24",{"date":387,"type":23},"2028-05",{"name":40,"class":41},{"id":390,"slug":391,"hasResults":12,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":4,"eligibilityCriteria":395,"healthyVolunteers":12,"sex":50,"minAge":19,"maxAge":396,"enrollmentInfo":397,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":399,"conditions":400,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":42},"100369962","biomarkers-in-different-types-of-amyotrophic-lateral-sclerosis-als-patients-being-treated-with-edaravone-100369962","NCT04097158","Biomarkers in Different Types of Amyotrophic Lateral Sclerosis (ALS) Patients Being Treated With Edaravone","Oxidative Markers and Efficacy in Amyotrophic Lateral Sclerosis (ALS) Phenotypes Treated With Edaravone","Inclusion Criteria:\n\n1. Either possible, probable, or definite ALS, predominantly lower motor neuron disease, predominantly upper motor neuron disease, or bulbar\n2. With or without cognitive involvement\n3. Willing to participate\n4. On no experimental treatment\n5. Ages 18 - 85\n6. No prior exposure to Edaravone (Radicava)\n7. On a stable dose of Riluzole for 30 days or off Riluzole\n8. Male or female\n9. Females of childbearing age must use contraception\n\nExclusion Criteria:\n\n1. Unstable medical illness\n2. Abnormal liver function (\\>2x ULN)\n3. Unlikely to survive for 26 weeks","85 Years",{"count":398,"type":23},160,"This study is being conducted to help the investigators better understand how the new FDA approved medication Edaravone (also known as Radicava) works in subsets of patients with ALS. The investigators are also trying to understand if there are specific ALS patients, with different presentations of ALS, who might benefit most from this medication. Also, the investigators are following specific biomarkers to determine the optimal treatment duration in patients with different forms of ALS\n\nThere is no study medication being offered in this trial. Edaravone is prescribed as part of regular care. In this trial we are collecting blood, urine, and spinal fluid samples in ALS patients who are taking Edaravone and ALS patients who are not taking Edaravone to measure certain markers that could indicate why the drug may be working in a specific type of ALS.",[401],"Amyotrophic Lateral Sclerosis","2026-06-03",{"date":334,"type":34},{"date":405,"type":34},"2019-10-08",{"date":407,"type":23},"2027-04",{"name":40,"class":41},{"id":410,"slug":411,"hasResults":12,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":4,"eligibilityCriteria":415,"healthyVolunteers":12,"sex":50,"minAge":19,"maxAge":4,"enrollmentInfo":416,"targetDuration":4,"studyType":24,"phases":418,"briefSummary":419,"conditions":420,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":422,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":427,"locationsCount":42},"100186044","proton-therapy-in-the-treatment-of-liver-metastases-100186044","NCT01697371","Proton Therapy in the Treatment of Liver Metastases","Phase I-II Trial of Stereotactic Body Proton Therapy for Patients With Liver Metastases","Inclusion Criteria:\n\nPathologically confirmed non-lymphoma liver metastases or\n\nNew radiographic liver lesions consistent with metastases in patients with known pathologically confirmed non-lymphoma cancer\n\n1-3 liver lesions measurable on CT\u002FMRI or PET\u002FCT performed within 6 weeks prior to study entry\n\nLiver metastases measuring \\\u003C5cm\n\nLife expectancy \\>6 months\n\nDisease outside the liver is allowed\n\nAge ≥ 18\n\nECOG Performance Scale = 0-1\n\nAdequate bone marrow function, defined as follows:\n\n* Absolute neutrophil count (ANC) ≥ 1,000 cells\u002Fmm3 based upon CBC\u002Fdifferential obtained within 4 weeks prior to registration on study\n* Platelets ≥ 60,000 cell\u002Fmm3 based upon CBC\u002Fdifferential obtained within 4 weeks prior to registration on study\n* Hemoglobin ≥ 8.0 g\u002Fdl based upon CBC\u002Fdifferential obtained within 4 weeks prior to registration on study (Note: the use of transfusion or other intervention to achieve Hgb ≥ 8.0 is acceptable.)\n\nAdequate kidney function (serum creatinine \\\u003C2mg\u002FdL) based on chemistry panel obtained within 4 weeks prior to registration on study\n\nAdequate liver function, defined as total bilirubin \\\u003C5 mg\u002FdL, serum albumin \\>2.0g\u002FdL, serum levels of liver enzymes \\\u003C 5 times the upper limit of normal, and INR \\\u003C 1.5\n\nPrevious liver resection or ablative therapy is permitted\n\nChemotherapy and\u002For targeted agent therapy must be completed at least 2 weeks prior to radiation and started at least 14 days after completion of SBPT Women of childbearing potential and male participants must practice adequate contraception\n\nPatient must sign study specific informed consent prior to study entry\n\nPretreatment evaluations required for eligibility include:\n\n* A complete history and general physical examination\n* For women of childbearing potential, a serum or urine pregnancy test must be performed within 72 hours prior to registration\n* INR, total bilirubin, albumin, alkaline phosphatase, ALT, AST within 4 weeks prior to study entry\n\nExclusion Criteria:\n\nPrior invasive malignancy other than liver met primary (except non-melanomatous skin cancer) unless disease free for \\> 3years\n\nPrior radiotherapy that would results in overlap of radiation fields\n\nPrior radiotherapy to the liver\n\nSevere, active co-morbidity that may impact survival\n\nCNS metastases\n\nTense ascites requiring frequent paracentesis\n\nActive liver infection\n\nPregnancy, nursing women, or women of child bearing potential, and men who are sexually active and not willing\u002Fable to use medically acceptable forms of contraception\n\nMetastases location within 2cm of GI tract\n\n\\-",{"count":417,"type":23},35,[26],"Local control of hepatic metastases appears to be a major determinant of overall survival. However, many patients are not suitable for resection due to medical or surgical reasons. Therefore, there is an important role for a treatment that can provide the equivalent of tumor resection with minimal morbidity. Stereotactic body radiotherapy (SBRT) delivers an ablative regimen of highly focused external beam radiotherapy that targets one or more discrete extracranial lesions. Published reports using SBRT to treat liver metastases have shown actuarial local control rates ranging from 50-100% with higher doses associated with better local control.\n\nIn patients with metastatic liver disease, aggressive local therapy using modern radiotherapy techniques are promising and project to have a substantial role in the treatment of metastatic liver cancer to treat unresectable disease. The dosimetric advantage of proton therapy may lead to improved clinical outcomes with less morbidity, however, there is no clinical data to confirm this assertion. We thus propose a phase I study to determine the feasibility and safety of stereotactic body proton therapy in patients with liver metastases followed by a phase II study to determine the efficacy of such treatment on local control.",[421],"Liver Metastases",{"date":334,"type":34},{"date":424,"type":34},"2012-08-22",{"date":426,"type":23},"2033-09",{"name":40,"class":41},{"id":429,"slug":430,"hasResults":12,"nctId":431,"briefTitle":432,"officialTitle":433,"acronym":4,"eligibilityCriteria":434,"healthyVolunteers":12,"sex":50,"minAge":19,"maxAge":4,"enrollmentInfo":435,"targetDuration":4,"studyType":24,"phases":437,"briefSummary":438,"conditions":439,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":441,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":446,"locationsCount":42},"100185087","proton-therapy-for-esophageal-cancer-100185087","NCT01684904","Proton Therapy for Esophageal Cancer","A Phase II Trial of Proton Chemotherapy (PCT) for Resectable Esophageal or Esophagogastric Junction Cancer","Inclusion Criteria:\n\n* Pathologically confirmed primary squamous cell or adenocarcinoma of the esophagus that involves the mid, distal or esophagogastric junction. The cancer may involve the stomach up to 5 cm.\n* Endoscopy with biopsy\n* Stage T1N102, T2-3N0-2 according to the American Joint Committee on Cancer (AJCC) 7th edition staging, based upon the following minimum diagnostic work-up:\n\nHistory\u002Fphysical examination with documentation of patient's weight within 30 days of registration\n\nChest\u002FAbdominal\u002FPelvic contrast CT within 56 days of registration\n\nWhole body PET\u002FCT within 56 days of registration\n\nEndoscopic ultrasound\n\nPatients may have regional adenopathy including para-esophageal, gastric, gastroheptaic and celiac nodes. If celiac adenopathy present, it must be ≤ 2cm.\n\nPatients with tumors at the level of the carina or above should undergo bronchoscopy to exclude fistula\n\nPulmonary function test (including routine spirometry and DLCO) within 60 days prior to registration\n\nSerum creatinine ≤ 2 x the upper limit of normal within 4 weeks of registration\n\nNa, K, BUN, Glucose within 4 weeks prior to registration\n\nCBC\u002Fdifferential within 4 weeks prior to registration with adequate bone marrow function, defined as follows:\n\n* Absolute neutrophil count (ANC) ≥ 1,500 cells\u002Fmm3\n* Platelets ≥ 100,000 cell\u002Fmm3\n* Hemoglobin ≥ 8.0 g\u002Fdl (Note: the use of transfusion or other intervention to achieve Hgb ≥ 8.0 is acceptable.)\n\nAdequate liver function, defined as total bilirubin ≤ 1.5 x upper limit of normal, AST ≤ 3 x the upper limit of normal within 4 weeks of registration\n\nAge ≥ 18\n\nZubrod performance status 0-2 within 4 weeks of registration\n\nSurgical consultation to confirm that patient will be able to undergo curative resection after completion of PCT prior to registration\n\nFor women of childbearing potential, a negative serum pregnancy test within 14 days prior to registration\n\nWomen of childbearing potential and male participants must practice adequate contraception while on study\n\nPatient must sign study specific informed consent prior to study entry\n\nExclusion Criteria:\n\nPatients with cervical esophageal carcinoma\n\nPatients with T1N0 disease and T4 disease\n\nPrior radiation for esophageal cancer or prior chest radiotherapy\n\nPrior chemotherapy for esophageal cancer\n\nEvidence of tracheoesophageal fistula or invasion into the trachea or major bronchi\n\nPrior invasive malignancy (except non-melanomatous skin cancer), unless disease free for a minimum of 2 years ( e.g. carcinoma in situ of breast, oral cavity, or cervix are permissible)\n\nPrior radiotherapy that would results in overlap of radiation fields\n\nMedical contraindications to esophagectomy\n\nPrior allergic reaction to paclitaxel or carboplatin\n\nSevere, active co-morbidity that may impact survival\n\nPregnancy, nursing women, or women of child bearing potential, and men who are sexually active and not willing\u002Fable to use medically acceptable forms of contraception\n\n\\-",{"count":436,"type":23},38,[26],"The goal of this phase II study is to investigate the feasibility, toxicity and efficacy of a regimen incorporating a proven systemic regimen, carboplatin \u002Fpaclitaxel, with conformal proton modality, followed by definitive surgery. In most combined-modality trials to date, chemotherapy regimens have included cisplatin, usually in conjunction with 5-fluorouracil.\n\nIn designing the regimen, the investigators attempt to improve on the standard cisplatin\u002F5-fluorouracil regimen in several ways. First, full-dose paclitaxel is added to the regimen. This agent has activity against advanced esophageal cancer and is also a potent radiosensitizer. Second, the substitution of carboplatin for cisplatin has resulted in reduced toxicity of various combination regimens similar to that used by CROSS trial and allows for easier administration in the outpatient setting.4 Third, for localized esophageal cancer, dose distribution patterns achievable with proton beam could potentially offer important clinical advantages relative to those achievable with x-rays (photons).19 Based on this, the investigators believe that this study should be conducted with the radiation modality that offers the best dosimetry achievable at our institution.",[440],"Esophagus Cancer",{"date":334,"type":34},{"date":443,"type":34},"2013-02-20",{"date":445,"type":23},"2032-08",{"name":40,"class":41},{"id":448,"slug":449,"hasResults":12,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":4,"eligibilityCriteria":453,"healthyVolunteers":17,"sex":50,"minAge":270,"maxAge":454,"enrollmentInfo":455,"targetDuration":4,"studyType":24,"phases":457,"briefSummary":458,"conditions":459,"keywords":461,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":469,"locationsCount":42},"100602999","blood-flow-restriction-training-as-a-targeted-intervention-for-rowers-with-back-pain-100602999","NCT07130812","Blood Flow Restriction Training as a Targeted Intervention for Rowers With Back Pain.","Breaking the Cycle of Low Back Pain: Blood Flow Restriction Training (BFR) as a Targeted Intervention for Rowers","Inclusion Criteria:\n\n* Aged 13-20 years old\n* Currently active rower (training ≥3 days\u002Fweek or 12 hours\u002Fweek)\n* Mild LBP with a low reactivity (\\\u003C3\u002F10) or recurring LBP within the past 18 months that has affected attendance to team practices\u002Fraces.\n* Able to complete a 2,000-meter rowing erg test\n\nExclusion Criteria:\n\n* Have severe or acute back pain that limits basic movement or requires medical treatment\n* History of spinal surgery or structural spine conditions (scoliosis requiring bracing\u002Fsurgery)\n* Have a contraindication to BFR training, identified via BFR safety screening form:\n* Peripheral vascular disease (PVD)\n* History of vascular surgery in arms or legs\n* Skin grafts on arms or legs\n* Arteriovenous fistula in limbs\n* Cognitive or physical impairment that limits participation\n* Hypertension or high blood pressure (uncontrolled or undiagnosed)\n* Bleeding disorders (e.g., hemophilia)\n* Blood clotting disorders (e.g., lupus, factor-V Leiden)\n* Past history of DVT or pulmonary embolism (PE)\n* Surgery in the past 12 weeks\n* Recent limb immobilization (e.g., cast, boot) in the last 4 weeks\n* History of stroke or transient ischemic attack (TIA)\n* History of cancer\n* Diagnosed heart disease\n* History of rhabdomyolysis\n* Diagnosed diabetes\n* Sickle cell disease\n* History of compartment syndrome\n* History of nerve damage or injury\n* Any prior complications or adverse reactions to BFR training\n* Any other medical conditions that should be cleared by a physician before starting BFR\n* Pregnancy(Self-reported)","20 Years",{"count":456,"type":23},120,[26],"The purpose of this graduate student research study is to compare the effects of low-load blood flow restriction training (LL-BFR) and heavy-load training (HLT) in high-volume rowers with mild low back pain or recurrent low back pain (LBP), aiming to determine whether LL-BFR offers a safer yet equally effective alternative to HLT for enhancing performance and reducing risk of re-injury.",[460],"Low Back Pain",[462],"blood flow restriction","2026-05-14",{"date":465,"type":34},"2026-05-18",{"date":467,"type":34},"2025-09-29",{"date":89,"type":23},{"name":40,"class":41},{"id":471,"slug":472,"hasResults":12,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":4,"eligibilityCriteria":476,"healthyVolunteers":12,"sex":50,"minAge":477,"maxAge":4,"enrollmentInfo":478,"targetDuration":4,"studyType":24,"phases":479,"briefSummary":480,"conditions":481,"keywords":483,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":486,"lastUpdatePostDateStruct":487,"startDateStruct":489,"completionDateStruct":491,"leadSponsor":493,"locationsCount":42},"100639860","to-evaluate-the-preliminary-efficacy-of-our-digitally-enhanced-chw-led-intervention-in-newly-diagnosed-pdac-100639860","NCT07591571","To Evaluate the Preliminary Efficacy of Our Digitally Enhanced CHW-led Intervention in Newly Diagnosed PDAC","To Evaluate the Preliminary Efficacy of Our Digitally Enhanced CHW-led Intervention in Newly Diagnosed PDAC With a Pilot Randomized Controlled Trial of 60 PDAC Patients and Their Caregivers Comparing the Intervention to Attention Control With Usual Care.","Inclusion criteria:\n\n* Age 18 to 90\n* English or Spanish-Speaking\n* Diagnosed with Newly-Diagnosed Pancreatic Adenocarcinoma or has a pancreatic mass on CT\u002FMRI with suspected PDAC and is awaiting biopsy.\n* Able to communicate verbally to allow for audio recording to complete an exit interview\n* Must be able to consent\n\nExclusion criteria:\n\n• Biopsy Does not Confirm Adenocarcinoma of the Pancreas","18 Months",{"count":22,"type":23},[26],"The goal of this clinical trial is to learn if a community health worker led intervention that helps facilitate palliative care works to treat newly-diagnostic pancreatic cancer. It will also help understand the impact of this intervention on people who are caregivers for patients with pancreatic cancer. The main questions it aims to answer are:\n\nDoes the community health worker improve symptoms and quality of life in patients with pancreatic cancer? Does the community health worker improve the burden of caregiving and quality of life in family caregivers? Researchers will compare drug ABC to a control (where patients get the care that patients with pancreatic cancer receive including access to handouts and videos that the investigators provide patients by national organizations) to see if the intervention works to help patients with pancreatic cancer.\n\nParticipants will:\n\nMeet with study staff several times over 3 months and complete surveys about their experience and symptoms Patients assigned with the community health worker will meet with them in person or video.",[482],"Pancreatic Cancer, Adult",[332,484,485],"pancreatic cancer","palliative care","2026-05-11",{"date":488,"type":34},"2026-05-15",{"date":490,"type":34},"2025-09-01",{"date":492,"type":23},"2026-09-01",{"name":40,"class":41},{"id":495,"slug":496,"hasResults":12,"nctId":497,"briefTitle":498,"officialTitle":499,"acronym":4,"eligibilityCriteria":500,"healthyVolunteers":17,"sex":50,"minAge":19,"maxAge":501,"enrollmentInfo":502,"targetDuration":4,"studyType":24,"phases":504,"briefSummary":505,"conditions":506,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":508,"lastUpdatePostDateStruct":509,"startDateStruct":511,"completionDateStruct":513,"leadSponsor":514,"locationsCount":42},"100539702","intermittent-fasting-on-body-fat-and-quality-of-life-100539702","NCT06307275","Intermittent Fasting on Body Fat and Quality of Life","The Effect of Intermittent Fasting on Body Fat and Quality of Life","Inclusion Criteria:\n\n• In good health\n\nExclusion Criteria:\n\n• Diabetes or Metabolic Syndrome","65 Years",{"count":503,"type":23},70,[26],"The purpose of this investigator-initiated study to check the feasibility that intermittent fasting has on body fat loss and quality of life.",[507],"Healthy","2026-04-30",{"date":510,"type":34},"2026-05-06",{"date":512,"type":34},"2024-03-11",{"date":89,"type":23},{"name":40,"class":41},{"id":516,"slug":517,"hasResults":12,"nctId":518,"briefTitle":519,"officialTitle":519,"acronym":4,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":50,"minAge":19,"maxAge":4,"enrollmentInfo":521,"targetDuration":4,"studyType":24,"phases":522,"briefSummary":523,"conditions":524,"keywords":531,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":535,"startDateStruct":537,"completionDateStruct":539,"leadSponsor":540,"locationsCount":42},"100593048","emotional-brain-training-for-addiction-medicine-treatment---a-pilot-study-100593048","NCT07001371","Emotional Brain Training for Addiction Medicine Treatment - A Pilot Study","Inclusion Criteria:\n\n* Age 18 years old or older\n* Patient can speak and read English\n* Patient who receives regular MAT care at SAC Health\n* Patients who have regular and reliable cellular and\u002For reliable internet connection\n* Patients who are willing to spend average of 25 minutes per day and attend weekly group meetings\n* Patients willing to actively participate in group sessions\n* Opioid use disorder, at least in early remission\n* Alcohol use disorder, at least in early remission\n* Methamphetamine use disorder, at least in early remission\n* Cocaine use disorder, at least in early remission\n* Anxiolytic use disorder, at least in early remission\n* Cannabis use disorder\n* Tobacco use disorder\n\nExclusion Criteria:\n\n* Age \\\u003C18 years old\n* Patient does not speak or read English\n* Patients who do not seek regular MAT care at SAC Health\n* Patients with inconsistent or no access to cellular or internet connection\n* Any disorder that is uncontrolled\n* Any substance use disorder not in at least early remission\n* Any patient with complications related to use disorder\n* Patients enrolled in the Coachella Valley Rescue Mission patients a part of SAC Health\n* Anyone who, in the opinion of the investigators, would be unable to participate in an 8-week trial",{"count":249,"type":23},[26],"The goal of this clinical trial is to determine whether Emotional Brain Training (EBT), a behavioral modification method, can help manage stress and health problems related to addiction. EBT teaches skills to deactivate harmful circuits (automatic reactions) and activate healing circuits to quickly shift mood from negative to positive. Participants in the EBT group will receive focused, intensive instruction on using these skills to rewire unwanted brain circuits, with the aim of achieving lasting improvements in emotional health and quality of life. The study will assess whether EBT is an effective tool when added to standard of care (SOC), which includes medications for addiction treatment (MAT).\n\nResearchers will compare changes in stress, anxiety, and cravings after 8 weeks of EBT plus SOC versus SOC alone.\n\nParticipants:\n\n* will either continue receiving standard treatments (SOC) at the Addiction Recovery Clinic (ARC) at SAC Health in San Bernardino\n* or receive both EBT and SOC at ARC\n* in the SOC group will continue monthly visits at ARC and weekly counseling\n* in the EBT plus SOC group will continue monthly visits and weekly counseling at ARC, along with weekly EBT group sessions by telephone\n* will complete online assessments at weeks 0, 4, and 8 Upon completion of the study, all participants will resume SOC",[525,526,527,528,529,530],"Cannabis Use Disorder","Stimulant Use Disorder","Opioid Use Disorder","Tobacco Use Disorder","Alcohol Use Disorder","Sedative, Hypnotic, or Anxiolytic Use Disorders",[532,533],"early remission","sustained remission","2026-04-21",{"date":536,"type":34},"2026-04-23",{"date":538,"type":23},"2026-08",{"date":340,"type":23},{"name":40,"class":41},{"id":542,"slug":543,"hasResults":12,"nctId":544,"briefTitle":545,"officialTitle":545,"acronym":4,"eligibilityCriteria":546,"healthyVolunteers":17,"sex":50,"minAge":19,"maxAge":501,"enrollmentInfo":547,"targetDuration":4,"studyType":24,"phases":549,"briefSummary":550,"conditions":551,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":555,"startDateStruct":557,"completionDateStruct":558,"leadSponsor":560,"locationsCount":42},"100441029","strain-counterstrain-treatment-of-piriformis-pain-100441029","NCT05023005","Strain-Counterstrain Treatment of Piriformis Pain","Inclusion Criteria:\n\n* 18 to 65 years of age\n* Tender point (or trigger point) in piriformis muscle determined by physical exam\n\nExclusion criteria:\n\n* Less than 45 degrees of active hip flexion, less than 5 degrees of active hip internal rotation or less than 30 degrees of active hip external rotation, on side of affected piriformis\n* Unable to lay prone\n* Non-English speaker\n* Inability to attend 2 sessions within the same month\n* Active cancer\n* Pregnant\n* Diagnosis of lumbar radiculopathy\n* Greater than grade 1 lumbar spondylolisthesis\n* Presence of lumbar region Pars Defect\n* Receiving massage, acupuncture, chiropractic treatments, osteopathic treatments during study period.",{"count":548,"type":23},30,[26],"The purpose of this investigator-initiated study is to provide an efficient and non-invasive treatment option for pain caused by the piriformis muscle.",[552,553,554],"Low Back Pain, Mechanical","Piriformis Syndrome","Somatic Dysfunction of Sacral Region (Finding)",{"date":556,"type":34},"2026-04-24",{"date":114,"type":23},{"date":559,"type":23},"2027-09",{"name":40,"class":41},{"id":562,"slug":563,"hasResults":12,"nctId":564,"briefTitle":565,"officialTitle":566,"acronym":4,"eligibilityCriteria":567,"healthyVolunteers":12,"sex":50,"minAge":19,"maxAge":568,"enrollmentInfo":569,"targetDuration":4,"studyType":24,"phases":570,"briefSummary":571,"conditions":572,"keywords":575,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":577,"startDateStruct":578,"completionDateStruct":580,"leadSponsor":582,"locationsCount":42},"100434562","phase-4-effect-of-magnesium-sulfate-bolus-on-intraoperative-neuromonitoring-100434562","NCT04938765","Effect of Magnesium Sulfate Bolus on Intraoperative Neuromonitoring","Randomized and Placebo Controlled Study to Evaluate the Effect of Magnesium Sulfate on Intraoperative Neuromonitoring.","Inclusion Criteria.\n\n* Patients aged 18 to 80 years\n* Belonging to American Society of Anesthesiologists physical status (ASA) I, II\n* Undergoing elective spine or cranial surgery where intraoperative neuromonitoring including short latency somatosensory evoked potentials (SSEP or SEP) and transcranial electrical muscle motor evoked potentials recording from muscles (TceMEP or TcMEP or mMEP or MEP) is planned.\n\nExclusion Criteria:\n\n* Magnesium use within the last 2 days, either intravenous or oral supplements.\n* Patients with known electrolyte imbalances (Sodium \\\u003C135 or \\>145 mmol\u002FL OR Potassium \\\u003C 3.5 or \\> 5.0 mmol\u002FL, Magnesium \\>1.2 mmol\u002FL.\n* Severe cardiac or cardiac conduction disorders.\n* Severe pulmonary disease.\n* Patients with significant neuromuscular disorders or preexisting motor or sensory deficits other than focal upper limb neuropathy or focal cervical radiculopathy or mild cervical myelopathy.\n* Severe Renal disease - serum creatinine of \\> 2 mg\u002Fdl.\n* Pregnant or breastfeeding patients.\n* Unable to obtain adequate baseline SSEPs and MEPs.","80 Years",{"count":126,"type":23},[232],"Magnesium Sulfate(MgSo4) is increasingly being used as part of the multimodal pain regimen in the perioperative period. The intraoperative neurophysiological monitoring (IONM) is utilized in complex spine and cranial surgeries to assess the functional integrity of the neural pathways. The effect of Magnesium sulfate on IONM has not been studied.\n\nThis is a prospective, double blind, randomized placebo controlled trial to study the effect of Magnesium sulfate bolus on the amplitude and latency of somatosensory(SSEPs) and motor evoked potentials(MEPs) in patients undergoing surgery requiring IONM.",[573,574],"Intraoperative Neurophysiological Monitoring","Magnesium Sulfate",[576],"multimodal analgesia",{"date":556,"type":34},{"date":579,"type":34},"2022-03-18",{"date":581,"type":23},"2027-03",{"name":40,"class":41},{"id":584,"slug":585,"hasResults":12,"nctId":586,"briefTitle":587,"officialTitle":588,"acronym":589,"eligibilityCriteria":590,"healthyVolunteers":12,"sex":50,"minAge":19,"maxAge":4,"enrollmentInfo":591,"targetDuration":4,"studyType":24,"phases":593,"briefSummary":594,"conditions":595,"keywords":599,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":604,"lastUpdatePostDateStruct":605,"startDateStruct":607,"completionDateStruct":609,"leadSponsor":610,"locationsCount":4},"100634200","relief-efficacy-of-lidocaine-versus-morphine-for-acute-renal-colic-in-the-emergency-department-100634200","NCT07536594","Relief Efficacy of Lidocaine Versus Morphine for Acute Renal Colic in the Emergency Department","RELIEF-RC: Relief Efficacy of LIdocaine Versus morphinE For Acute Renal Colic in the Emergency Department","RELIEF-RC","Inclusion Criteria:\n\nIn order to be eligible for inclusion in the study, an individual must meet all of the following criteria:\n\n* Age ≥ 18 years at time of visit\n* Able and willing to consent for participation in study\n* Documentation of suspected renal colic as primary complaint as evidenced by reported flank pain, back pain, abdominal pain, or groin pain, or as determined by the treating clinician\n* Requires additional treatment due to inadequate analgesia or clinical suspicion of unsafe discharge secondary to pain after initial treatment with parenteral ketorolac\n\nExclusion Criteria:\n\nAny individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Age \\\u003C 18 years\n* Use of analgesia for renal colic within 6 hours prior to clinician evaluation\n* Inability or unwillingness to consent for participation in study\n* Experienced a severe adverse event that required clinician intervention after initial treatment with parenteral ketorolac\n* Documented history of allergic or anaphylactic reaction to NSAIDs, lidocaine, or morphine\n* Documented history of cardiac arrhythmias\n* Documented history of chronic use of opioid medications for unrelated diagnoses\n* Currently pregnant\n* Documented history of end-stage renal or hepatic dysfunction\n* Clinical contraindications to NSAIDs, lidocaine, or morphine per clinician discretion",{"count":592,"type":23},250,[26],"The opioid epidemic continues to be a major public health crisis in the United States. According to the Center for Disease Control, approximately 8 million Americans reported misusing prescription opioids in 2023, with over 5 million Americans reporting that they suffer from opioid use disorder. The United States government estimates that 105,000 people died from drug overdose in 2023, and approximately 80,000 of those deaths can be attributed to opioids (\\~76%). In acknowledgement of the opioid crisis, we wish to contribute to ongoing efforts to reduce unnecessary and excessive opioid prescription.\n\nIn 2012, researchers in Iran published a randomized controlled trial comparing intravenous (IV) lidocaine to IV morphine for acute renal colic, reporting that 90% patients responded \"successfully\" in the lidocaine group versus 70% in the morphine group. They also concluded that there was a statistically significant difference between pain scores between the two groups at all time points, favoring the lidocaine group. However, the study was conducted at a single emergency department in Tabriz, Iran, with a relatively homogenous patient population, and the researchers did not explicitly define their primary outcome variable for what constituted a \"successful\" response in the treatment groups. The investigators of this study aim to build upon this preliminary evidence by recruiting a more diverse population to improve generalizability and by predefining pain-reduction thresholds to allow for more meaningful comparison between the interventions.",[596,597,598],"Renal Colic","Kidney Stones, Urolithiasis, Hypocitraturia","Opioid Use During Medical Care",[600,601,602,603],"renal colic","kidney stones","lidocaine","opioid use","2026-04-15",{"date":606,"type":34},"2026-04-17",{"date":608,"type":23},"2026-06",{"date":309,"type":23},{"name":40,"class":41},""]